OncoMatch/Clinical Trials/NCT06300528
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Is NCT06300528 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pemigatinib for relapsed or refractory b-cell non-hodgkin lymphoma.
Treatment: Pemigatinib — The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: fgfr inhibitor
Lab requirements
Blood counts
ANC ≥ 1000/mm3 independent of G-CSF support (no G-CSF within past 3 days), unless bone marrow involvement or splenomegaly with cytopenia (then ANC ≥ 750/mm3 allowed); Platelet count ≥ 75,000/mm3 independent of transfusion support (no transfusion within past 3 days), unless bone marrow involvement (then ≥ 50,000/mm3 allowed); Hemoglobin ≥ 8 g/dL independent of transfusion support (no transfusion within past 3 days), unless bone marrow involvement or splenomegaly with cytopenia (then ≥ 7 g/dL allowed); no evidence of myelodysplasia or hypoplastic bone marrow.
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula.
Liver function
Total Bilirubin ≤ 1.5x institutional ULN or <2.5 x ULN with documented liver involvement and/or Gilbert's disease; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN; subjects with liver involvement allowed with AST and ALT ≤ 5 x ULN.
Cardiac function
No congestive heart failure NYHA Class III or IV, serious cardiac arrhythmias, unstable angina or acute coronary syndrome within 2 months, MI within 3 months, QTcF > 470 ms (unless corrected), LVEF < 40% in prior 12 months.
Adequate organ function as defined as: Hematologic: ANC ≥ 1000/mm3...; Platelet count ≥ 75,000/mm3...; Hemoglobin ≥ 8 g/dL...; Hepatic: Total Bilirubin ≤ 1.5x institutional ULN...; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN...; Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify